search
Back to results

Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection

Primary Purpose

Lumbar Spinal Stenosis, Lumbar Disc Herniation, Scoliosis Lumbar Region

Status
Unknown status
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Teicoplanin
Sponsored by
Bezmialem Vakif University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Lumbar Spinal Stenosis focused on measuring Spine Surgery, Teicoplanin powder, Surgical site infection, Posterior lumbar instrumentation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Lumbar spinal stenosis,
  • LDH(Lumbar Disc Hernia)
  • Lumbar degenerative scoliosis
  • Lumbar spondylolisthesis

Exclusion Criteria:

  • History of malignancy
  • Systemic inflammatory disease
  • Severe cardiac insufficiency
  • Morbid obesity (>40 kg/m2 or 35 or more and experiencing obesity-related health conditions)
  • History of lumbar spine surgery

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    No Intervention

    Arm Label

    Group 1

    Group 2

    Arm Description

    We will be added 200mg teicoplanin powder around instrument for each level.

    We will not used any antibiotic powder in this group.

    Outcomes

    Primary Outcome Measures

    Surgical site infection
    Surgical site infection rates will be compared between two goups

    Secondary Outcome Measures

    Full Information

    First Posted
    April 8, 2020
    Last Updated
    April 10, 2020
    Sponsor
    Bezmialem Vakif University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04341831
    Brief Title
    Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection
    Official Title
    Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    April 15, 2020 (Anticipated)
    Primary Completion Date
    January 15, 2021 (Anticipated)
    Study Completion Date
    April 15, 2021 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Bezmialem Vakif University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    Infection after spinal surgery is one of the serious complications. Spinal surgery infection can cause high morbidity, mortality, and costs. In spite of different prophylactic methods, up to 15% of infection appears after spinal surgery. Vancomycin powder, which is one of the most applied methods, seems to be effective and inexpensive. However, vancomycin administration may be inconvenient in elderly participants with high comorbidity and especially kidney problems. The investigators aimed to reduce the rate of infection in the post-op 90-day period by adding per-op Teicoplanin powder onto the implant in participants scheduled for lumbar posterior instrumentation.
    Detailed Description
    Study Design: The investigators will start trial after our institution's Clinical Research Ethics Committee approval. The protocol conforms to CONSORT guidelines for parallel-group randomized trials and the protocol is designed to conform to the principles of the Declaration of Helsinki. Participant : A literature review revealed that the surgical site infection rates after posterior instrumentation to be around 13-15%. Being a non-inferiority trial, the investigators hypothesized that the 90-day surgical site infection rates after posterior lumbar instrumentation should not be more than 1%. In order to find the difference of 14.0% between the two groups statistically significant, the minimum number of subjects required in each group was determined to be 55. (Power of 80 % and significance level at 0.05). To account for missing data, the drop-out rate was set to 10% and therefore, a total of 60 participants will be randomized. The investigators will be included participants with spinal stenosis, LDH(Lumbar Disc Hernia), degenerative scoliosis or spondylolisthesis who did not respond to conservative treatment and participants in whom operation will be planned in the only lumbar spine. The investigators will be excluded participants with a history of malignancy, systemic inflammatory disease, severe cardiac insufficiency, morbid obesity (>40 kg/m2 or 35 or more and experiencing obesity-related health conditions) and participants who had undergone spine surgery previously. An informed consent form will be obtained from all participants. The schedule for randomization will be randomly generated using a computer before the initiation of the trial. Participants will randomly be assigned in a 1:1 ratio. The investigators planned our study as double-blinded. Neither participants nor assessors will know about randomization results. The outcome assessor will be blinded to group allocation and won't be involved in providing the interventions. The statistician performing the statistical analyses will be blinded to group allocation. Surgical procedures: All surgeries will be performed by one surgeon under general anesthesia. The investigators will be used rod and pedicle screws of the same brand in all participants (Tasarım Med, Turkey)- using a standard posterior midline approach. All participants will be given 2 g cefazolin for infection prophylaxis and 1 g tranexamic acid for blood loss prophylaxis intravenously 30 min before the incision. In group 1 Teicoplanin powder will be placed on the rod and pedicle screws. The investigators will be added 200mg. teicoplanin powder around the instrument for each level. Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site. All participants will be undergoing the same post-op rehabilitation protocol.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Lumbar Spinal Stenosis, Lumbar Disc Herniation, Scoliosis Lumbar Region, Lumbar Spondylolisthesis, Lumbar Disc Lesion
    Keywords
    Spine Surgery, Teicoplanin powder, Surgical site infection, Posterior lumbar instrumentation

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    120 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Group 1
    Arm Type
    Experimental
    Arm Description
    We will be added 200mg teicoplanin powder around instrument for each level.
    Arm Title
    Group 2
    Arm Type
    No Intervention
    Arm Description
    We will not used any antibiotic powder in this group.
    Intervention Type
    Drug
    Intervention Name(s)
    Teicoplanin
    Other Intervention Name(s)
    Targocid
    Intervention Description
    We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
    Primary Outcome Measure Information:
    Title
    Surgical site infection
    Description
    Surgical site infection rates will be compared between two goups
    Time Frame
    90 days

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Lumbar spinal stenosis, LDH(Lumbar Disc Hernia) Lumbar degenerative scoliosis Lumbar spondylolisthesis Exclusion Criteria: History of malignancy Systemic inflammatory disease Severe cardiac insufficiency Morbid obesity (>40 kg/m2 or 35 or more and experiencing obesity-related health conditions) History of lumbar spine surgery
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Murat Sarıkaş, MD
    Phone
    00905414346105
    Email
    msarikas@bezmialem.edu.tr
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Murat Sarıkaş, MD
    Organizational Affiliation
    Bezmialem Vakif University
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Does Teicoplanin Powder Use In Lumbar Instrumentation Surgery Reduce Surgical Site Infection

    We'll reach out to this number within 24 hrs